Pharmacokinetics of Cyclosporine a Conversion From Twice-Daily Infusion to Oral Administration in Allogeneic Hematopoietic Stem Cell Transplantation
Authors:
- Tasuku SaitoTSTasuku Saito
- Kohei OgawaKOKohei Ogawa
- Yuji NishioYNYuji Nishio
- Shigeki KosugiSKShigeki Kosugi
- Yoshinori SuzukiYSYoshinori Suzuki
- Masayuki KatoMKMasayuki Kato
- Hirotaka SakaiHSHirotaka Sakai
- Masatomo TakahashiMTMasatomo Takahashi
- Ikuo MiuraIMIkuo Miura
- 1 September 2014
- journal article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 21 (5) , 377-384
Abstract
Twice-daily administration of cyclosporine A (CyA) has often been used for prophylaxis of acute graft versus host disease in allogeneic hematopoietic stem cell transplantation (allo-HSCT). But there have not been any reports that calculated the conversion ratio of the switch from twice-daily intravenous infusion to oral administration of CyA in adult patients. To establish the conversion ratio and the best strategy of twice-daily administration of CyA, the authors investigated the serial changes in the blood CyA concentration during the switch from twice-daily intravenous infusion to oral administration while maintaining high-peak concentration (over 1000 ng/mL) and calculated the bioavailability of Neoral, a micro emulsion cyclosporine, in 11 patients. All the patients underwent allo-HSCT with graft versus host disease prophylaxis consisting of CyA at a high-peak concentration of twice-daily infusion with short-term methotrexate and oral administration. Neoral was started at an oral dose, 2 times daily, at twice the latest dose of intravenous dose according to the bioavailability of healthy volunteers. Micafungin, a mild inhibitor of CYP3A4, was administered for prophylaxis against fungal infection. The total area under the concentration-time curve during oral administration (AUCpo) was nearly the same as AUC during intravenous infusion (AUCiv) (mean ± SD, 7206 ± 1557 ng·h·mL and 7783 ± 897.7 ng·h·mL, respectively). The bioavailability of Neoral, defined as F = AUCpo × DOSEiv/AUCiv × DOSEpo was 0.58 ± 0.15 (mean ± SD, range: 0.41-0.94). When patients were switched from twice-daily infusion to oral administration, the dose conversion ratio of 1:2 seemed to be appropriate. At that time, the target trough level of Neoral was nearly the same as that of the infusion.Keywords
This publication has 18 references indexed in Scilit:
- Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of AliskirenThe Journal of Clinical Pharmacology, 2011
- Benefits of cyclosporine absorption profiling in nephrotic syndrome: Preprandial once‐daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profileNephrology, 2007
- Functional interactions between P-glycoprotein and CYP3A in drug metabolismExpert Opinion on Drug Metabolism & Toxicology, 2005
- Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphomaTransplantation and Cellular Therapy, 2005
- Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II studyTransplantation and Cellular Therapy, 2002
- Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studiesBlood, 2001
- Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in JapanBone Marrow Transplantation, 2001
- Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationBlood, 2001
- Comparison of a Monoclonal Antibody Fluorescent Polarization Immunoassay with Monoclonal Antibody Radioimmunoassay for Cyclosporin Determination in Whole BloodTherapeutic Drug Monitoring, 1992
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974